Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Other financing activities (2021 - 2023)

Actinium Pharmaceuticals (ATNM) has disclosed Other financing activities for 3 consecutive years, with $927000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Other financing activities fell 5.31% to $927000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $3.8 million, a 37.46% increase, with the full-year FY2023 number at $3.8 million, up 37.46% from a year prior.
  • Other financing activities was $927000.0 for Q4 2023 at Actinium Pharmaceuticals, up from $921000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.0 million in Q2 2023 to a low of $376000.0 in Q1 2021.
  • A 3-year average of $694250.0 and a median of $690000.0 in 2021 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: dropped 7.41% in 2022, then soared 135.87% in 2023.
  • Actinium Pharmaceuticals' Other financing activities stood at $447000.0 in 2021, then surged by 119.02% to $979000.0 in 2022, then fell by 5.31% to $927000.0 in 2023.
  • Per Business Quant, the three most recent readings for ATNM's Other financing activities are $927000.0 (Q4 2023), $921000.0 (Q3 2023), and $1.0 million (Q2 2023).